Category «APPROVALS 2022»

Gefapixant citrate

Gefapixant Molecular FormulaC14H19N5O4S Average mass353.397 Da 1015787-98-0 [RN] 10642 AF 217 5-[(2,4-Diamino-5-pyrimidinyl)oxy]-4-isopropyl-2-methoxybenzenesulfonamide 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benzene- sulfonamide Gefapixant Citrate Formula C14H19N5O4S. C6H8O7 CAS 2310299-91-1 Mol weight 545.5203 APPROVED JAPAN PMDA 2022/1/20, Lyfnua ゲーファピキサントクエン酸塩吉法匹生 Efficacy Analgesic, Anti-inflammatory, Antitussive, P2X3 receptor antagonist Comment Treatment of disorders associated with purinergic receptor activation Gefapixant (MK-7264) is a drug which acts as an antagonist of the P2RX3 receptor, and may …

Daridorexant

Daridorexant Molecular FormulaC23H23ClN6O2 Average mass450.921 Da [(2S)-2-(5-Chloro-4-methyl-1H-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl][5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone 1505484-82-1 [RN] Methanone, [(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl][5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl]- ACT-541468, , Nemorexant FDA APPROVED 2022, 1/7/2022, To treat insomnia, Quviviq Daridorexant HCl CAS#: 1792993-84-0 (HCl) Chemical Formula: C23H24Cl2N6O2 Molecular Weight: 487.39 Elemental Analysis: C, 56.68; H, 4.96; Cl, 14.55; N, 17.24; O, 6.57 Methanone, ((2S)-2-(6-chloro-7-methyl-1H-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)-, hydrochloride (1:1) Daridorexant HCl; Daridorexant hydrochloride; ACT541468A; ACT 541468A; ACT-541468A; ACT541468 …

OTESECONAZOLE

OTESECONAZOLE VT 1161 オテセコナゾール; (2R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(tetrazol-1-yl)-1-[5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl]propan-2-ol C23H16F7N5O2 527.4 Synonyms VT 1161 Oteseconazole 1340593-59-0 Other Names (αR)-α-(2,4-Difluorophenyl)-β,β-difluoro-α-(1H-tetrazol-1-ylmethyl)-5-[4-(2,2,2-trifluoroethoxy)phenyl]-2-pyridineethanol (2R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-1,2,3,4-tetrazol-1-yl)- 1-{5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl}propan-2-ol UPDATE MAY 2022… FDA APPROVED 2022/4/26, Vivjoa Oteseconazole, sold under the brand name Vivjoa, is a medication used for the treatment of vaginal yeast infections.[1] It was approved for medical use in the United States in April 2022.[2][3] It was developed by Mycovia Pharmaceuticals.[3] …

NOVAWAX, NVX-CoV2373,

NOVAWAX NVX-CoV2373 SARS-CoV-2 rS Nanoparticle Vaccine MCDC OTA agreement number W15QKN-16-9-1002 Novavax COVID-19 vaccine, Coronavirus disease 19 infection SARS-CoV-2 rS, TAK 019 Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. As of 2020, it had an ongoing Phase III clinical trial in older adults for its candidate vaccine for seasonal influenza, NanoFlu and a candidate vaccine (NVX-CoV2373) …

MITAPIVAT

MITAPIVAT CAS 1260075-17-9 MF C24H26N4O3S MW 450.55 UPDATE…. FDA APPROVE 2/17/2022 To treat hemolytic anemia in pyruvate kinase deficiency, Pyrukynd митапиват [Russian] [INN] ميتابيفات [Arabic] [INN] 米他匹伐 [Chinese] [INN] 10226 1260075-17-9 [RN] 2WTV10SIKH AG-348 8-Quinolinesulfonamide, N-[4-[[4-(cyclopropylmethyl)-1-piperazinyl]carbonyl]phenyl]- N-[4-[[4-(Cyclopropylmethyl)-1-piperazinyl]carbonyl]phenyl]-8-quinolinesulfonamide Originator Agios Pharmaceuticals Class Antianaemics; Piperazines; Quinolines; Small molecules; Sulfonamides Mechanism of Action Pyruvate kinase stimulants Orphan Drug Status Yes – Inborn error metabolic disorders New Molecular Entity Yes Phase III Inborn …